Cargando…
Overview of the Development and Use of Akt Inhibitors in Prostate Cancer
Deregulation of the PI3K-Akt-mTOR pathway plays a critical role in the development and progression of many cancers. In prostate cancer, evidence suggests that it is mainly driven by PTEN loss of function. For many years, the development of selective Akt inhibitors has been challenging. In recent pha...
| Autores principales: | , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
MDPI
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8745410/ https://www.ncbi.nlm.nih.gov/pubmed/35011901 http://dx.doi.org/10.3390/jcm11010160 |
| _version_ | 1784630337708490752 |
|---|---|
| author | Gasmi, Anis Roubaud, Guilhem Dariane, Charles Barret, Eric Beauval, Jean-Baptiste Brureau, Laurent Créhange, Gilles Fiard, Gaëlle Fromont, Gaëlle Gauthé, Mathieu Ruffion, Alain Renard-Penna, Raphaële Sargos, Paul Rouprêt, Morgan Ploussard, Guillaume Mathieu, Romain |
| author_facet | Gasmi, Anis Roubaud, Guilhem Dariane, Charles Barret, Eric Beauval, Jean-Baptiste Brureau, Laurent Créhange, Gilles Fiard, Gaëlle Fromont, Gaëlle Gauthé, Mathieu Ruffion, Alain Renard-Penna, Raphaële Sargos, Paul Rouprêt, Morgan Ploussard, Guillaume Mathieu, Romain |
| author_sort | Gasmi, Anis |
| collection | PubMed |
| description | Deregulation of the PI3K-Akt-mTOR pathway plays a critical role in the development and progression of many cancers. In prostate cancer, evidence suggests that it is mainly driven by PTEN loss of function. For many years, the development of selective Akt inhibitors has been challenging. In recent phase II and III clinical trials, Ipatasertib and Capivasertib associated with androgen deprivation therapies showed promising outcomes in patients with metastatic castration-resistant prostate cancer and PTEN-loss. Ongoing trials are currently assessing several Akt inhibitors in prostate cancer with different combinations, at different stages of the disease. |
| format | Online Article Text |
| id | pubmed-8745410 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2021 |
| publisher | MDPI |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-87454102022-01-11 Overview of the Development and Use of Akt Inhibitors in Prostate Cancer Gasmi, Anis Roubaud, Guilhem Dariane, Charles Barret, Eric Beauval, Jean-Baptiste Brureau, Laurent Créhange, Gilles Fiard, Gaëlle Fromont, Gaëlle Gauthé, Mathieu Ruffion, Alain Renard-Penna, Raphaële Sargos, Paul Rouprêt, Morgan Ploussard, Guillaume Mathieu, Romain J Clin Med Review Deregulation of the PI3K-Akt-mTOR pathway plays a critical role in the development and progression of many cancers. In prostate cancer, evidence suggests that it is mainly driven by PTEN loss of function. For many years, the development of selective Akt inhibitors has been challenging. In recent phase II and III clinical trials, Ipatasertib and Capivasertib associated with androgen deprivation therapies showed promising outcomes in patients with metastatic castration-resistant prostate cancer and PTEN-loss. Ongoing trials are currently assessing several Akt inhibitors in prostate cancer with different combinations, at different stages of the disease. MDPI 2021-12-29 /pmc/articles/PMC8745410/ /pubmed/35011901 http://dx.doi.org/10.3390/jcm11010160 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
| spellingShingle | Review Gasmi, Anis Roubaud, Guilhem Dariane, Charles Barret, Eric Beauval, Jean-Baptiste Brureau, Laurent Créhange, Gilles Fiard, Gaëlle Fromont, Gaëlle Gauthé, Mathieu Ruffion, Alain Renard-Penna, Raphaële Sargos, Paul Rouprêt, Morgan Ploussard, Guillaume Mathieu, Romain Overview of the Development and Use of Akt Inhibitors in Prostate Cancer |
| title | Overview of the Development and Use of Akt Inhibitors in Prostate Cancer |
| title_full | Overview of the Development and Use of Akt Inhibitors in Prostate Cancer |
| title_fullStr | Overview of the Development and Use of Akt Inhibitors in Prostate Cancer |
| title_full_unstemmed | Overview of the Development and Use of Akt Inhibitors in Prostate Cancer |
| title_short | Overview of the Development and Use of Akt Inhibitors in Prostate Cancer |
| title_sort | overview of the development and use of akt inhibitors in prostate cancer |
| topic | Review |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8745410/ https://www.ncbi.nlm.nih.gov/pubmed/35011901 http://dx.doi.org/10.3390/jcm11010160 |
| work_keys_str_mv | AT gasmianis overviewofthedevelopmentanduseofaktinhibitorsinprostatecancer AT roubaudguilhem overviewofthedevelopmentanduseofaktinhibitorsinprostatecancer AT darianecharles overviewofthedevelopmentanduseofaktinhibitorsinprostatecancer AT barreteric overviewofthedevelopmentanduseofaktinhibitorsinprostatecancer AT beauvaljeanbaptiste overviewofthedevelopmentanduseofaktinhibitorsinprostatecancer AT brureaulaurent overviewofthedevelopmentanduseofaktinhibitorsinprostatecancer AT crehangegilles overviewofthedevelopmentanduseofaktinhibitorsinprostatecancer AT fiardgaelle overviewofthedevelopmentanduseofaktinhibitorsinprostatecancer AT fromontgaelle overviewofthedevelopmentanduseofaktinhibitorsinprostatecancer AT gauthemathieu overviewofthedevelopmentanduseofaktinhibitorsinprostatecancer AT ruffionalain overviewofthedevelopmentanduseofaktinhibitorsinprostatecancer AT renardpennaraphaele overviewofthedevelopmentanduseofaktinhibitorsinprostatecancer AT sargospaul overviewofthedevelopmentanduseofaktinhibitorsinprostatecancer AT roupretmorgan overviewofthedevelopmentanduseofaktinhibitorsinprostatecancer AT ploussardguillaume overviewofthedevelopmentanduseofaktinhibitorsinprostatecancer AT mathieuromain overviewofthedevelopmentanduseofaktinhibitorsinprostatecancer |